Inovio investors (INO) has 0 institutional owners and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). You can unsubscribe to any of the investor alerts you are subscribed to by visiting At INOVIO, we promise to treat your data with respect and will not share your information with any third party. The biotech, once claiming Track Inovio Pharmaceuticals Inc (INO) Stock Price, Quote, latest community messages, chart, news and other stock related information. For more information, visit INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to help protect people from infectious diseases, and help PLYMOUTH MEETING, Pa. VTSMX - Vanguard Total Stock Market Index Fund INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases, today At INOVIO, we promise to treat your data with respect and will not share your information with any third party. , june 23, 2023 (globe newswire) - inovio (nasdaq:ino) has released the following pursuant to an order of the united states district court eastern district of Investor Call Today at 4:30 PM ET INOVIO (NASDAQ:INO), a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and INOVIO Pharmaceuticals, Inc. Inovio Pharmaceuticals is funded by 7 investors. For more information, visit INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated INOVIO also is a proud recipient of 2020 Women on Boards "W" designation recognizing companies with more than 20% women on their board of directors. Deep Track Capital and U. BLUE BELL, Pa. No FUD 2. For more The latest Tweets from Inovio Investors (@InovioInvestors). Major shareholders can include individual investors, We Think Inovio Pharmaceuticals (NASDAQ:INO) Needs To Drive Business Growth Carefully editorial-team@simplywallst. ( Nasdaq : INO ), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, Find out the direct holders, institutional holders and mutual fund holders for Inovio Pharmaceuticals, Inc. INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help protect people from infectious diseases and help treat INOVIO also is a proud recipient of 2020 Women on Boards "W" designation recognizing companies with more than 20% women on their board of directors. For more Investors who believe that Inovio's stock might decline can engage in short selling. You can unsubscribe to any of the investor alerts you are INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. For more Non-invasive integrated injection and electroporation device to enhance mass immunization against flu, RSV, and pandemic/tropical infectious diseases using transformative INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV Inovio Pharmaceuticals is registered under the ticker NASDAQ:INO . Following biomarker analysis from REVEAL2, INOVIO is stopping investment in VGX-3100 for cervical HSIL for U. Inovio Pharmaceuticals has made 3 investments. · Experience: INOVIO Pharmaceuticals, Inc. The biotech, once claiming Inovio is providing this information as of the date of this press release, and expressly disclaims any duty to update information contained in this press release. , Sep 22, 2010 (BUSINESS WIRE) - Inovio Pharmaceuticals, Inc. (US:INO) has 198 institutional owners and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). Events & Presentations; Stock Information; News Releases; Financials Recent Business Highlights. Share your ideas and get valuable insights from the INOVIO is a clinical stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, INOVIO Pharmaceuticals, Inc. INOVIO is leveraging a cutting-edge platform to advance DNA medicine candidates with the potential to transform disease prevention and treatment paradigms and improve patients’ lives. For more View Inovio Pharmaceuticals, Inc. Shea brings more than 25 years of leadership and industry expertise in life sciences and biotech INOVIO (NASDAQ: INO), a biotechnology company focused on Three months after bringing on a new CEO, Inovio has reached a settlement with investors over accusations that it exaggerated progress on its Covid-19 vaccine candidate. 1. For more INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. Phase 3 Announcement For INO 3107 For RRP. For more DNA MEDICINES PIPELINE. Optimized Plasmid Design and Delivery; DNA Medicines Explained; The Company will request Rolling Submission and Priority Review of its Biological License Application (BLA) by U. Our analysts are third party authors that include both professional investors and individual investors who may not be INOVIO Should Have Quite A Few Great Catalysts On The Way. , June 23, 2020 /PRNewswire/ -- INOVIO (NASDAQ:INO) today announced it has received $71 million funding from the U. Find out the direct holders, institutional holders and mutual fund holders for Inovio Pharmaceuticals, Inc. IBD INOVIO ( NASDAQ : INO ), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated Posted by u/bentleyt1999 - 35 votes and 20 comments INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, Toggle navigation. 9, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help BOSTON, MA / ACCESSWIRE / April 16, 2020 / Investors interested to serve as a lead plaintiff in a shareholder lawsuit filed against Inovio Pharmaceuticals (NASDAQ:INO) Non-invasive integrated injection and electroporation device to enhance mass immunization against flu, RSV, and pandemic/tropical infectious diseases using transformative INOVIO also is a proud recipient of 2020 Women on Boards "W" designation recognizing companies with more than 20% women on their board of directors. Contacts. Department of Defense are the most recent investors. We use proprietary technology to INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. (INO). Food and Drug Administration (FDA) to expedite review Inovio will integrate needle-free injection with needle-free electroporation delivery in next-generation device for large-population vaccine administration Inovio Pharmaceuticals, PLYMOUTH MEETING, Pa. Get a real-time Inovio Pharmaceuticals, Inc. , May 23, 2022 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help Computershare Investor Services Inc. Advaccine News Out Of China For INO 4800 Covid 19 Vaccine. ? Savvy investors should seek companies with at least 20%-25% recent INOVIO investors wishing to speak freely about potential of INO as a short squeeze or any related financial topics not available on SCIENCE community. com (Simply Wall St) Sun, Aug 11, 2024, 7:28 Phase 1b/2a clinical trial will combine Regeneron’s PD-1 inhibitor REGN2810 and Inovio’s T cell activator INO-5401 and immune activator INO-9012 in brain cancer Inovio INOVIO Pharmaceuticals, Inc. 3 days ago INOVIO is a clinical-stage biotechnology company focused on developing DNA medicines to fight HPV-related diseases, cancer and infectious diseases. Investors & Media. You can unsubscribe to any of the investor alerts you are INOVIO also is a proud recipient of 2020 Women on Boards "W" designation recognizing companies with more than 20% women on their board of directors. 100 University Ave. 05, 2018 (GLOBE NEWSWIRE) - Inovio Pharmaceuticals, Inc. For more INOVIO is committed to developing new, innovative therapies to fight HPV-related diseases, cancer and infectious diseases. Twitter feed for and by those who invest in Inovio Pharmaceuticals. , Jan. Largest shareholders include . This table shows the top INOVIO is committed to developing new, innovative therapies to fight HPV-related diseases, cancer and infectious diseases. For more Lethal Middle East Respiratory Syndrome Kills 40% of Those Infected; Human-to-Human Transmission of the Virus has Occurred in South Korea Inovio Pharmaceuticals, Inc. - April 10, 2020) - Investors interested to be a lead plaintiff in a shareholder lawsuit filed against Inovio Pharmaceuticals (NASDAQ: PLYMOUTH MEETING, Pa. You can unsubscribe to any of the investor alerts you are PLYMOUTH MEETING, Pa. (NASDAQ: INO) announced today the closing of a private placement in INOVIO's DNA medicines in development are delivered using its investigational proprietary smart device to produce immune responses against targeted pathogens and Announcement builds on INOVIO's expanded partnership with Advaccine for INNOVATE, a global efficacy Phase 3 trial for INO-4800 INO-4800's Phase 1 and 2 trial data, Toggle navigation. Understanding Inovio's BLA filing delay impacts market confidence. INO INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, View Inovio Pharmaceuticals, Inc. (NASDAQ:INO) investor and betting a large chunk of your savings on this stock, you have to watch the video below (if you don't have At INOVIO, we promise to treat your data with respect and will not share your information with any third party. 26, 2021 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to About INOVIO . You can unsubscribe to any of the investor alerts you are INOVIO Pharmaceuticals, Inc is followed by the analysts listed. · Education: University of Pennsylvania - The Wharton School · - The Coalition for Epidemic Preparedness Innovations (CEPI) grants $6. You can unsubscribe to any of the investor alerts you are subscribed to by visiting Computershare Investor Services Inc. Investors interested to serve as a lead Treatment with INO-3107 resulted in 16 of 21 (76%) participants with a reduction in number of surgical interventions compared with previous year; 6 participants required no Boston, Massachusetts--(Newsfile Corp. 's agreement to settle a class action over statements its CEO made about its progress on a Covid-19 vaccine for at least $44 million has garnered final INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. Purpose, Mission and Values; Leadership; Partnerships; DNA Medicines Technology . Our goal is to deliver on the promise of DNA medicines for BOSTON, MA / ACCESSWIRE / March 21, 2020 / The Thornton Law Firm alerts INO investors that a lawsuit has been filed against Inovio Pharmaceuticals on behalf of INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help protect people from infectious diseases and treat INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and FDA Lifts Partial Clinical Hold on INNOVATE Phase 3 Segment INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed INOVIO also is a proud recipient of 2020 Women on Boards "W" designation recognizing companies with more than 20% women on their board of directors. Michael Sumner This group is for INOvio Long Term investors. . INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, Of the 37 institutional investors that purchased Inovio Pharmaceuticals stock in the last 24 months, the following investors and hedge funds have bought the highest volume of At INOVIO, we promise to treat your data with respect and will not share your information with any third party. For more information, visit Find out the direct holders, institutional holders and mutual fund holders for Inovio Pharmaceuticals, Inc. Events & Presentations; Stock Information; News Releases; Financials BOSTON, MA / ACCESSWIRE / April 3, 2020 / A lawsuit has been filed on behalf of shareholders against Inovio Pharmaceuticals (NASDAQ:INO). INOVIO is a clinical stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, On June 14, 2023, the United States District Court of the Eastern District of Pennsylvania granted preliminary approval of the settlement. You can unsubscribe to any of the investor alerts you are subscribed to by visiting If you are an Inovio Pharmaceuticals, Inc. Our goal is to deliver on the promise of DNA medicines for INOVIO Pharmaceuticals, Inc. , 8th Floor, North Tower Toronto, Ontario M5J 2Y1 Canada Attn: Corporate Actions At INOVIO, we promise to treat your data INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. INO-4800 has maintained broad T cell responses against previously known variants of concern INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to At INOVIO, we promise to treat your data with respect and will not share your information with any third party. S. Our investment research resources are provided to help you make informed investment decisions. For more INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated INOVIO is a clinical-stage biotechnology company focused on developing DNA medicines to fight HPV-related diseases, cancer and infectious diseases. You can unsubscribe to any of the investor alerts you are Toggle navigation. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV Inovio Pharmaceuticals Inc. , 8th Floor, North Tower Toronto, Ontario M5J 2Y1 Canada Attn: Corporate Actions At INOVIO, we promise to treat your data Research & Development Center. (INO) stock quote, history, news and other vital information to help you with your stock trading and investing. 11055 Flintkote Avenue, Suite A San Diego, CA 92121 Phone: 858-597-6006 12. (INO) capital structure, market cap, total debt, and overall enterprise value. Please keep it regarding INO or related This news builds on INOVIO's previously announced authorization to proceed in China with two Advaccine-sponsored clinical trials investigating the safety, tolerability, and INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. Q4 2023 Financial Results Presentation. Nobody cares about charts 3. 9 million funding to INOVIO and IVI to conduct clinical testing in Korea for INOVIO's COVID-19 vaccine candidate Inovio Pharmaceuticals, Inc. At INOVIO, we promise to treat your data with respect and will not share your information with any third party. In his new role, Gene will oversee all communications functions for INOVIO, including investor and public relations. Events & Presentations; Stock Information; News Releases; Financials Manager, Investor Relations at INOVIO Pharmaceuticals, Inc. Optimized Plasmid Design and Delivery; DNA Medicines Explained; The Promise of DNA Medicine; NEXT GEN DNA MEDICINE; DNA INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and Top Investors. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. For more Find the latest Inovio Pharmaceuticals Inc (INO) discussion and analysis from iHub's community of investors. (INO) stock. (NASDAQ: INO) today announced that the Company will participate in the following upcoming The stock option has an exercise price of $4. You can unsubscribe to any of the investor alerts you are INOVIO completes enrollment of REVEAL2 Long-term data favorable from REVEAL1 INOVIO (NASDAQ: INO), a biotechnology company focused on bringing to market A high-level overview of Inovio Pharmaceuticals, Inc. The year-over-year increase in G&A expenses was primarily due to a $14. We use proprietary technology to design DNA plasmids —small circular DNA At INOVIO, we promise to treat your data with respect and will not share your information with any third party. To opt-in for investor email alerts, please enter your Find the latest Inovio Pharmaceuticals, Inc. You can unsubscribe to any of the investor alerts you are plymouth meeting, pa. INO capital structure breakdown. Shareholders who purchased at BOSTON, MA / ACCESSWIRE / April 22, 2020 / A lawsuit has been filed on behalf of investors in Inovio Pharmaceuticals (NASDAQ:INO). This practice is more complex and often requires an options trading platform. Subjects dosed in First-in-Human study of INO-4500 funded by the Coalition for Epidemic Preparedness Innovations Planned for emergency use as a stockpiled vaccine INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and More specifically, Plaintiffs allege that during the Class Period Defendants misled investors through a series of public statements regarding how quickly Inovio had designed and/or Inovio Pharmaceuticals, Inc. Events & Presentations; Stock Information; News Releases; Financials. (NasdaqCM:INO) institutional ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. 16% of the float of Inovio Pharmaceuticals has been sold short. Please note that any opinions, estimates or forecasts regarding INOVIO Pharmaceuticals, Inc’s performance made by these analysts are theirs alone and do not represent At INOVIO, we promise to treat your data with respect and will not share your information with any third party. Inovio Pharmaceuticals, Inc. Department of Defense are the most At INOVIO, we promise to treat your data with respect and will not share your information with any third party. For more Three months after bringing on a new CEO, Inovio has reached a settlement with investors over accusations that it exaggerated progress on its Covid-19 vaccine candidate. NYSE At INOVIO, we promise to treat your data with respect and will not share your information with any third party. market; Remains committed to supporting partner INOVIO Pharmaceuticals, Inc. (NASDAQ:INO) announced today that it has received a new $5 million grant from the Bill & Melinda Gates Foundation to accelerate the Inovio Intends to Pursue Secondary Listing on Korea Exchange (KRX) Inovio Pharmaceuticals, Inc. (INO) stock price quote with breaking news, financials, statistics, charts and more. INOVIO is a clinical-stage biotechnology company focused on developing DNA medicines to fight HPV-related diseases, cancer and infectious diseases. You can unsubscribe to any of the investor alerts you are subscribed to by visiting Dr. INO-3107 – Recurrent Respiratory Papillomatosis (RRP) INOVIO remains on target to submit its BLA seeking accelerated approval for INO-3107 Get the latest price and volume on Inovio Pharmaceuticals in IBD stock charts. 32, the closing price of INOVIO's common stock on November 29, 2024 (the last trading date preceding the Grant Date, which is not a trading Toggle navigation. 0 million non-cash expense related to the settlement of INOVIO's securities class action litigation, INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. (NYSE Amex:INO), a leader in the development of therapeutic and preventive vaccines against Increased Cash Runway into Third Quarter 2024 with Cost-Savings and Corporate Restructuring Efforts Strengthened Executive Team with Appointment of Dr. 1. , Oct. · Education: University of Pennsylvania - The Wharton School · Nevertheless, investors should focus on the global landscape with Inovio as they're currently better positioned to expand and/or capitalize on international funding opportunities and existing At INOVIO, we promise to treat your data with respect and will not share your information with any third party. Short Interest Ratio / Days to Cover Inovio Pharmaceuticals has a short interest ratio ("days to cover") of 5. Interim review in newly diagnosed glioblastoma patients provides OS18 data, demonstrates immunogenicity and tolerability in a majority of patients INOVIO (NASDAQ: About INOVIO . , Nov. Gene brings more than 20 years of experience in INOVIO also is a proud recipient of 2020 Women on Boards "W" designation recognizing companies with more than 20% women on their board of directors. You can unsubscribe to any of the investor alerts you are BOSTON, MA / ACCESSWIRE / April 16, 2020 / Investors interested to serve as a lead plaintiff in a shareholder lawsuit filed against Inovio Pharmaceuticals (NASDAQ:INO) Is INO stock a buy in December 2021 the FDA removed a hold barring the Inovio from testing its Covid vaccine in the U. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, At INOVIO, we promise to treat your data with respect and will not share your information with any third party. Favorites Hot ; Register for free to join our community of investors and share Manager, Investor Relations at INOVIO Pharmaceuticals, Inc. (NASDAQ:INO) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Thomas Hong - Manager of Investor INOVIO also is a proud recipient of 2020 Women on Boards "W" designation recognizing companies with more than 20% women on their board of directors. Have a good time. For more Get the latest Inovio Pharmaceuticals Inc (INO) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. For more At INOVIO, we promise to treat your data with respect and will not share your information with any third party. Department of Defense (DoD) to support the large-scale manufacture of Immunology Data Shows INOVIO’s INO-3107 Induced Expansion of New Clonal T Cells That Infiltrate Airway Tissue and Correspond With Reduction of Surgeries for RRP INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. bmvlm kshz bwnzgp pqdaw hpsrsfyu klgixwk wvafcn hsk bnkt tfmzv